IPHA
Income statement / Annual
Last year (2023), Innate Pharma S.A.'s total revenue was $51.90 M,
an increase of 4.56% from the previous year.
In 2023, Innate Pharma S.A.'s net income was -$7.57 M.
See Innate Pharma S.A.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$51.90 M |
$49.64 M |
$12.11 M |
$69.77 M |
$68.97 M |
$79.89 M |
$32.63 M |
$56.16 M |
$17.91 M |
$907,000.00 |
| Cost of Revenue |
$56.02 M
|
$51.66 M
|
$47.00 M
|
$49.71 M
|
$45.16 M
|
$69.56 M
|
$67.00 M
|
$48.63 M
|
$29.91 M
|
$12.09 M
|
| Gross Profit |
-$4.12 M
|
-$2.02 M
|
-$34.89 M
|
$20.07 M
|
$23.82 M
|
$10.34 M
|
-$34.37 M
|
$7.53 M
|
-$12.00 M
|
-$11.18 M
|
| Gross Profit Ratio |
-0.08
|
-0.04
|
-2.88
|
0.29
|
0.35
|
0.13
|
-1.05
|
0.13
|
-0.67
|
-12.33
|
| Research and Development Expenses |
$56.02 M
|
$51.66 M
|
$47.00 M
|
$49.71 M
|
$1.60 M
|
$69.56 M
|
$67.00 M
|
$48.63 M
|
$29.91 M
|
$22.67 M
|
| General & Administrative Expenses |
$11.75 M
|
$14.47 M
|
$15.99 M
|
$18.58 M
|
$40.73 M
|
$18.14 M
|
$15.66 M
|
$8.88 M
|
$5.59 M
|
$12.50 M
|
| Selling & Marketing Expenses |
$0.00
|
$7.96 M
|
$9.53 M
|
$408,000.00
|
$8.85 M
|
$1.11 M
|
$527,000.00
|
$450,000.00
|
$288,000.00
|
$314,000.00
|
| Selling, General & Administrative Expenses |
$11.75 M
|
$22.44 M
|
$25.52 M
|
$18.99 M
|
$49.58 M
|
$19.25 M
|
$16.18 M
|
$9.33 M
|
$5.88 M
|
$12.82 M
|
| Other Expenses |
-$3.20 M
|
-$8.04 M
|
-$12.59 M
|
-$49.71 M
|
-$309,000.00
|
-$14.06 M
|
-$10.57 M
|
-$9.37 M
|
-$7.11 M
|
-$19,000.00
|
| Operating Expenses |
$64.57 M
|
$66.06 M
|
$59.94 M
|
$18.99 M
|
$50.87 M
|
$74.75 M
|
$72.61 M
|
$48.59 M
|
$28.68 M
|
$8.76 M
|
| Cost And Expenses |
$64.57 M
|
$66.06 M
|
$59.94 M
|
$68.69 M
|
$96.03 M
|
$74.75 M
|
$72.61 M
|
$48.59 M
|
$28.68 M
|
$20.85 M
|
| Interest Income |
$3.18 M
|
$4.78 M
|
$6.34 M
|
$0.00
|
$1.62 M
|
$1.58 M
|
$1.25 M
|
$0.00
|
$27,000.00
|
$445,000.00
|
| Interest Expense |
$640,000.00
|
$5.32 M
|
$4.00 M
|
$0.00
|
$204,000.00
|
$102,000.00
|
$113,000.00
|
$124,000.00
|
$139,000.00
|
$0.00
|
| Depreciation & Amortization |
$5.09 M
|
$4.42 M
|
$4.57 M
|
$12.23 M
|
$16.53 M
|
$7.40 M
|
$4.40 M
|
$3.26 M
|
$2.66 M
|
$2.34 M
|
| EBITDA |
-$1.84 M |
-$61.30 M |
-$43.23 M |
$13.31 M |
-$20.86 M |
-$3.30 M |
-$35.65 M |
$10.83 M |
-$8.09 M |
-$17.14 M |
| EBITDA Ratio |
-0.04
|
-1.23
|
-3.57
|
0.19
|
-0.3
|
-0.04
|
-1.09
|
0.19
|
-0.45
|
-18.9
|
| Operating Income Ratio |
-0.24
|
-0.23
|
-3.95
|
0.02
|
-0.39
|
0.06
|
-1.23
|
0.13
|
-0.6
|
-22.01
|
| Total Other Income/Expenses Net |
$5.10 M
|
-$547,000.00
|
$2.35 M
|
-$1.91 M
|
$6.29 M
|
-$2.43 M
|
-$8.03 M
|
$5.37 M
|
$4.07 M
|
$319,000.00
|
| Income Before Tax |
-$7.57 M
|
-$57.97 M
|
-$45.48 M
|
-$829,000.00
|
-$20.76 M
|
$2.72 M
|
-$48.02 M
|
$12.94 M
|
-$6.71 M
|
-$19.65 M
|
| Income Before Tax Ratio |
-0.15
|
-1.17
|
-3.75
|
-0.01
|
-0.3
|
0.03
|
-1.47
|
0.23
|
-0.37
|
-21.66
|
| Income Tax Expense |
$0.00
|
$41.13 M
|
$13.66 M
|
$0.00
|
$206,000.00
|
-$333,000.00
|
$368,000.00
|
$301,000.00
|
$139,000.00
|
-$24,000.00
|
| Net Income |
-$7.57 M
|
-$99.10 M
|
-$59.14 M
|
-$63.98 M
|
-$20.97 M
|
$3.05 M
|
-$48.39 M
|
$12.64 M
|
-$6.71 M
|
-$19.65 M
|
| Net Income Ratio |
-0.15
|
-2
|
-4.88
|
-0.92
|
-0.3
|
0.04
|
-1.48
|
0.23
|
-0.37
|
-21.66
|
| EPS |
-0.09 |
-1.24 |
-0.74 |
-0.0105 |
-0.31 |
0.0519 |
-0.89 |
0.23 |
-0.13 |
-0.39 |
| EPS Diluted |
-0.09 |
-1.24 |
-0.74 |
-0.0105 |
-0.31 |
0.0519 |
-0.89 |
0.23 |
-0.13 |
-0.39 |
| Weighted Average Shares Out |
$84.11 M
|
$79.64 M
|
$79.54 M
|
$6.09 B
|
$66.91 M
|
$58.78 M
|
$54.35 M
|
$53.87 M
|
$51.58 M
|
$50.15 M
|
| Weighted Average Shares Out Diluted |
$84.11 M
|
$79.64 M
|
$79.54 M
|
$78.93 M
|
$66.91 M
|
$58.78 M
|
$54.35 M
|
$53.87 M
|
$53.40 M
|
$50.15 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
